Positive Phase 3 Trial Results for EPIDIOLEX®

GW Pharmaceuticals has announced positive top-line results of a Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC).  This is exciting news and a step further along the path to a new treatment option for seizures caused by TSC.  Thank you to the Australians who took part in this international trial and the neurologists and study staff who were involved.

You can read more at:  https://www.globenewswire.com/news-release/2019/05/06/1817795/0/en/GW-Pharmaceuticals-Reports-Positive-Phase-3-Pivotal-Trial-Results-for-EPIDIOLEX-cannabidiol-Oral-Solution-in-Patients-with-Seizures-Associated-With-Tuberous-Sclerosis-Complex